Author

S. E. Dross

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

D. H. Fuller· 3 shared A. A. Cohen· 2 shared P. J. Bjorkman· 2 shared A. C. Sherman· 1 shared A. Dauphin· 1 shared A. I. Ramsingh· 1 shared A. J. Greaney· 1 shared A. P. West· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

D. H. Fuller

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

A. A. Cohen, J. R. Keeffe, A. Schiepers, S. E. Dross, A. J. Greaney, A. V. Rorick, H. Gao, P. N. P. Gnanapragasam, C. Fan, A. P. West, A. I. Ramsingh, J. H. Erasmus, J. D. Pata, H. Muramatsu, N. Pardi, , P. J. Bjorkman

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

bioRxiv · Feb 8, 2024Immunology

Protein design for evaluating vaccines against future viral variation

N. Youssef, S. Gurev, F. Ghantous, K. P. Brock, J. A. Jaimes, N. N. Thadani, A. Dauphin, A. C. Sherman, L. Yurkovetskiy, D. Soto, R. Estanboulieh, B. Kotzen, P. Notin, A. W. Kollasch, A. A. Cohen, , D. Marks

The paper designs SARS-CoV-2 Spike proteins with novel mutations to evaluate vaccine effectiveness against future viral variants using a deep learning model.

bioRxiv · Oct 8, 2023Immunology

Protection from viral rebound after therapeutic vaccination with an adjuvanted DNA vaccine is associated with SIV-specific polyfunctional CD8 T cells in the blood and mesenteric lymph nodes

H. C. Tunggal, P. V. Munson, M. A. O'Connor, N. Hajari, S. E. Dross, D. Bratt, J. T. Fuller, K. Bagley, D. H. Fuller

This study shows that a therapeutic DNA vaccine with adjuvants protects some SIV-infected macaques from viral rebound by enhancing polyfunctional CD8 T cells in blood and gut lymph nodes.

bioRxiv · Sep 16, 2020 · PreprintMicrobiology